Table 2.
Variables | Tumor upgrading on the surgical specimen |
p | |
---|---|---|---|
No (n = 59) | Yes (n= 111) | ||
Age, median (range) | 63.3 (52–57) | 65.0 (46–75) | 0.297 |
BMI, median (range) | 26.1 (20–34) | 26.4 (20–42) | 0.136 |
PSA, median (range) | 5.5 (0.75–9.69) | 6.05 (2.42–9.92) | 0.021 |
PV, median (range) | 40.0 (16–120) | 39.0 (15–110) | 0.038 |
P+, median (range) | 0.17 (0.05–0.60) | 0.29 (0.06–0.78) | 0.004 |
V+, median (range) | 5.0 (2.0–70.0) | 15.0 (2.0–70.0) | < 0.0001 |
W, median (range) | 53.0 (30–130) | 50.0 (23–129) | 0.196 |
cT | 0.141 | ||
1c, n (%) | 55 (36.7) | 95 (63.3) | |
2a, n (%) | 4 (20) | 16 (80) | 0.036 |
pT | |||
= 2 | 56 (37.6) | 93 (62.4) | |
> 2 | 3 (14.3) | 18 (85.7) |
PV = Prostate volume; P+ = proportion of biopsy positive cores; V+ = percentage of cancer related to volume of the prostate; W = prostate weight; cT = clinical tumor stage; pT = pathological tumor stage.